INTENSIVE NITROGEN MUSTARD THERAPY WITH ABDOMINAL AORTIC OCCLUSION IN NASOPHARYNGEAL CARCINOMA.
D000230:Adenocarcinoma; D000970:Antineoplastic Agents; D001011:Aorta; D001012:Aorta, Abdominal; D002066:Busulfan; D002277:Carcinoma; D002294:Carcinoma, Squamous Cell; D002561:Cerebrovascular Disorders; D010478:Chemotherapy, Cancer, Regional Perfusion; D004358:Drug Therapy; D005009:Ethoglucid; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D007035:Hypothermia; D007036:Hypothermia, Induced; D007630:Kenya; D008228:Lymphoma, Non-Hodgkin; D008466:Mechlorethamine; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms; D009364:Neoplasm Recurrence, Local; D009369:Neoplasms / Q000628:therapy*; D010166:Palliative Care; D011379:Prognosis; D011655:Pulmonary Embolism; D012509:Sarcoma; D014111:Tourniquets; D014116:Toxicology
D000970:Antineoplastic Agents; D005009:Ethoglucid; D008466:Mechlorethamine; D006493:Heparin; D002066:Busulfan
ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; AORTA, ABDOMINAL; BUSULFAN; CARCINOMA; CARCINOMA, EPIDERMOID; CEREBROVASCULAR DISORDERS; DRUG THERAPY; ETHOGLUCID; HEPARIN, THERAPEUTIC; HYPOTHERMIA, INDUCED; ISOLATION PERFUSION; KENYA; LYMPHOSARCOMA; MECHLORETHAMINE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM THERAPY; PALLIATIVE TREATMENT; PROGNOSIS; PULMONARY EMBOLISM; SARCOMA; TOURNIQUETS; TOXICOLOGIC REPORT